[go: up one dir, main page]

EP4058064A1 - Composition pour thérapie photodynamique antimicrobienne - Google Patents

Composition pour thérapie photodynamique antimicrobienne

Info

Publication number
EP4058064A1
EP4058064A1 EP20808310.5A EP20808310A EP4058064A1 EP 4058064 A1 EP4058064 A1 EP 4058064A1 EP 20808310 A EP20808310 A EP 20808310A EP 4058064 A1 EP4058064 A1 EP 4058064A1
Authority
EP
European Patent Office
Prior art keywords
composition
hydrogen peroxide
infection
light
photosensitizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20808310.5A
Other languages
German (de)
English (en)
Inventor
Jimmie Kert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cms Dental AS
Original Assignee
Cms Dental AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Dental AS filed Critical Cms Dental AS
Publication of EP4058064A1 publication Critical patent/EP4058064A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Definitions

  • composition for antimicrobial photodynamic therapy Composition for antimicrobial photodynamic therapy
  • the present invention relates to a composition and a kit of parts for antimicrobial photodynamic therapy and uses of the same.
  • the invention further relates a method of treating, ameliorating or reducing an infection or inflammation in the mouth cavity, such as gingivitis, periodontitis, peri- mucositis, peri-implantitis or endodontic infections.
  • Photodynamic therapy is a form of phototherapy that involves light and a photosensitizing chemical substance, used in conjunction with molecular oxygen to elicit cell death, such as death of pathogenic microorganism.
  • photodynamic therapy involves the use of non-toxic compound (porphyrins, chlorins or dyes) that act as photoactive drugs (referred to as photosensitizers) in combination with visible light of the appropriate wavelength to excite the photosensitizer.
  • photosensitizers non-toxic compound that act as photoactive drugs
  • the photosensitizer in the presence of the oxygen, transfers energy or electrons to ground state molecular oxygen producing reactive oxygen species (ROS) such as singlet oxygen and hydroxyl radical, which are responsible for the killing of cells.
  • ROS reactive oxygen species
  • Photodynamic therapy is an established modality for the treatment of cancer. It has also been extended for the treatment of noncancerous conditions such as age related macular degeneration and other dermatological applications. Besides these applications, there has also been a growing interest in the application of PDT for the treatment of infectious diseases. Elimination of pathogenic microorganisms by photodynamic therapy is termed antimicrobial PDT (aPDT). In the recent years, antimicrobial photodynamic therapy has drawn increasing attention from the dental practitioners for its potential in the treatment of oral infection, such periodontitis and endodontic infections.
  • the object of the present invention is to provide improved compositions for use in dentistry such as improved composition for antimicrobial photodynamic therapy and methods for using such compositions.
  • a first aspect of the present invention provides a composition comprising
  • a second aspect of the present invention provides a kit of parts comprising (a) a first container comprising a first composition comprising hydrogen peroxide, carbamide peroxide, sodium hypochlorite or any combination thereof,
  • a second container comprising a second composition comprising at least one photosensitizer capable of being activated by light emitted in the blue spectrum
  • (c) optionally a source of light emitting light in the blue spectrum.
  • a third aspect of the present invention provides a composition or kits of parts of the present invention for use in the treatment of an infection in the mouth cavity, such as gingivitis, periodontitis, periimplantitis, perimucositis, peri- implantitis or endodontic infections.
  • a further aspect of the present invention provides a method of treating, ameliorating or reducing an infection in the mouth cavity, said method comprising the steps of
  • the present invention provides a composition comprising
  • composition of the present invention is that treatment with the peroxide (hydrogen peroxide, carbamide peroxide, sodium hypochlorite or any combination thereof) and the photosensitizer(s) is performed simultaneously by co-administration. The treatment is thus faster and more comfortable for the patient.
  • the composition the peroxide (hydrogen peroxide, carbamide peroxide and/or sodium hypochlorite) and the photosensitizer(s) is stable for long-term storage.
  • the photosensitizer is a compound acceptable for application to the oral cavity.
  • the photosensitizer is a non toxic compound (or at least non-toxic in the amount applied) that act as photoactive drugs in combination with visible light comprising light emitted in the blue spectrum to excite the photosensitizer.
  • the photosensitizer(s) is activated by the light in the range of 380 to 520 nm, such as 405 to 470 nm, preferably 455 ⁇ 30 nm.
  • the photosensitizer(s) has a peak absorption around 455 nm, preferably 455 ⁇ 30 nm.
  • the photosensitizer is typically a porphyrin, chlorin or dye.
  • the photosensitizer(s) is a natural (non-synthetic) photosensitizer.
  • the photosensitizer(s) is selected from the group consisting of curcumin, riboflavin and erythrosine.
  • the photosensitizer is curcumin.
  • the photosensitizer is riboflavin.
  • the composition comprises least two photosensitizers, such as two, three, four or five photosensitizers capable of being activated by light emitted in the blue spectrum.
  • the composition comprises curcumin and riboflavin.
  • the composition comprises two photosensitizers, which are curcumin and riboflavin.
  • the composition comprises photosensitizer(s) in amounts sufficient to provide a therapeutic effect (treating, ameliorating or reducing the infection) in the dose applied to the infected area, for example a tooth pocket or a root canal of an infected tooth.
  • the composition comprises 0.001 to 0.1 wt% of said at least one photosensitizer, such as 0.01 to 0.1 wt% of the at least one photosensitizer.
  • the composition comprises 0.1 wt% of the at least one photosensitizer, such as 0.1 wt% curcumin, 0.1 wt% riboflavin, or a total of 0.1 wt% curcumin and riboflavin.
  • the composition comprises 0.01 wt% of the at least one photosensitizer, such as 0.01 wt% curcumin, 0.01 wt% riboflavin, or a total of 0.02 wt% curcumin and riboflavin.
  • the composition comprises 0.03 wt% of the at least one photosensitizer, such as 0.02 wt% curcumin, 0.01 wt% riboflavin, or a total of 0.03 wt% curcumin and riboflavin.
  • composition of the present invention comprises hydrogen peroxide, carbamide peroxide, sodium hypochlorite or any combination thereof.
  • the composition comprises hydrogen peroxide.
  • Hydrogen peroxide, carbamide peroxide and sodium hypochlorite work by producing destructive hydroxyl free radicals that can attack membrane lipids, DNA, and other essential cell components.
  • Catalase produced by aerobic organisms and facultative anaerobes that possess cytochrome systems, can protect cells from metabolically produced the peroxides by degrading the peroxides to water and oxygen. This defence mechanism is overwhelmed by the concentrations used for disinfection.
  • Hydrogen peroxide, carbamide peroxide and sodium hypochlorite have demonstrated antimicrobial activity against a wide range viruses, bacteria, yeasts, and bacterial spores. In general, greater activity is seen against Gram-positive than Gram-negative bacteria. Under normal conditions, Hydrogen peroxide, carbamide peroxide and sodium hypochlorite are stable when properly stored (e.g., in dark containers). The decomposition or loss of potency in small containers is low at ambient temperatures.
  • the composition comprises 0.25 to 5 wt% of hydrogen peroxide, carbamide peroxide or sodium hypochlorite or any combination thereof, such as 0.25 to 5 wt% of hydrogen peroxide, carbamide peroxide or sodium hypochlorite or any combination thereof, such as 0.25 to 5 wt% of hydrogen peroxide or 0.25 to 5 wt% of sodium hypochlorite.
  • the composition comprises hydrogen peroxide in the range of 2.5 to 4 wt% hydrogen peroxide, for example 2.5 to 3.5 wt% hydrogen peroxide, preferably 3 wt% hydrogen peroxide or about 3 wt% hydrogen peroxide.
  • the hydrogen peroxide may be provided in the form of carbamid peroxide.
  • Carbamide peroxide consist equal molar amounts of hydrogen peroxide (molar weight of 34.01 g/mol) and urea (molar weight of 60.06 g/mol).
  • the composition comprises 0.25 to 5 wt% of hydrogen peroxide and the hydrogen peroxide is provided in the form of carbamid peroxide
  • the composition further comprises about 0.44 to 8.8 wt% of urea.
  • the composition comprises carbamid peroxide corresponding to 2.5 to 4 wt% hydrogen peroxide (and thus about about 4.4 to 7.1 wt% of urea), for example 2.5 to 3.5 wt% hydrogen peroxide (and thus about about 4.4 to 6.2 wt% of urea), preferably 3 wt% hydrogen peroxide or about 3 wt% hydrogen peroxide (and thus about about 5.3 wt% of urea).
  • the composition comprises 0.69 to 13.8 wt% of carbamid peroxide.
  • the composition comprises carbamid peroxide in the range of 6.9 to 11.1 wt% carbamid peroxide, for example 6.9 to 9.7 wt% carbamid peroxide, preferably 8.3 wt% carbamid peroxide or about 8.3 wt% carbamid peroxide.
  • the composition comprises 3 wt% or about 3 wt% hydrogen peroxide. In another embodiment, the composition comprises 2.5 wt% or about 2.5 wt% sodium hypochlorite.
  • composition comprises a gelling agent.
  • the composition comprises a gelling agent selected from the group consisting of guar gum, gum acacia, tragacanth, sodium alginate, pectin, starch, gelatin, cellulose derivative (such as hydroxypropyl methyl cellulose, methylcellulose and sodium carboxymethyl cellulose), carbomers, polyvinyl pyrrolidone, polyvinyl alcohol and xanthan gum or any combination thereof.
  • the gelling agent is guar gum.
  • the amount of gelling agent in the composition may dependent on the gelling agent and the preferred viscosity of the gel.
  • the composition typically comprises 0.5% to 10 wt% of said gelling agent, for example about 7% to 10 wt% of of said gelling agent, for example about 7% to 9 wt% of of said gelling agent or such as 1, 2, 3, 4, 5, 6, 7, 8, or 9 wt% of said gelling agent.
  • the composition is typically provided in dry form for storage, such as a powder, which may be reconstituted to an aqueous gel briefly before use.
  • the composition comprises hydrogen peroxide, riboflavin, curcumin and guar gum.
  • hydrogen peroxide riboflavin
  • curcumin guar gum
  • the composition comprises about 3 wt% hydrogen peroxide, about 0.01 wt% curcumin, about 0.01 wt% riboflavin and about 0.5% to 10 wt% of guar gum, such as about 7% to 10 wt% of guar gum, for example about 7% to 9 wt% of guar gum, such as about 8 wt% of guar gum.
  • the composition comprises about 3 wt% hydrogen peroxide, about 0.02 wt% curcumin, about 0.01 wt% riboflavin and about 0.5% to 10 wt% of guar gum, such as about 7% to 10 wt% of guar gum, for example about 7% to 9 wt% of guar gum, such as about 8 wt% of guar gum.
  • the composition is provided in dry form, which may be reconstituted to an aqueous gel before use.
  • the composition may further comprises one or more additional acceptable excipients such as one or more of a preservative, one or more antioxidants, and/or a surfactant, which may contribute for example to the stability of the composition.
  • additional acceptable excipients such as one or more of a preservative, one or more antioxidants, and/or a surfactant, which may contribute for example to the stability of the composition.
  • a second aspect of the present invention provides a kit of parts (a) a first container comprising a first composition comprising hydrogen peroxide, carbamide peroxide, sodium hypoclorite or any combination thereof,
  • a second container comprising a second composition comprising at least one photosensitizer capable of being activated by light emitted in the blue spectrum
  • (c) optionally a source of light emitting light in the blue spectrum.
  • kits of part is provided without a source of light, in particular where a suitable source of light is already available in the dental clinic.
  • the kit comprises at least one photosensitizers selected from the group consisting of curcumin, riboflavin and erythrosine.
  • composition comprises two photosensitizers, such as curcumin and riboflavin.
  • the first composition of said kit comprises hydrogen peroxide, such as 0.25 to 5 wt% hydrogen peroxide, such as 2.5 to 4 wt% hydrogen peroxide, for example 2.5 to 3.5 wt% hydrogen peroxide, preferably 3 wt% hydrogen peroxide or about 3 wt% hydrogen peroxide.
  • hydrogen peroxide such as 0.25 to 5 wt% hydrogen peroxide, such as 2.5 to 4 wt% hydrogen peroxide, for example 2.5 to 3.5 wt% hydrogen peroxide, preferably 3 wt% hydrogen peroxide or about 3 wt% hydrogen peroxide.
  • the first and/or said second composition comprises a gelling agent.
  • the gelling agent is selected from the group consisting of guar gum, gum acacia, tragacanth, sodium alginate, pectin, starch, gelatin, cellulose derivative (such as hydroxypropyl methyl cellulose, methylcellulose and sodium carboxymethyl cellulose), carbomers, polyvinyl pyrrolidone, polyvinyl alcohol and xanthan gum.
  • the first and/or said second composition comprises 0.5% to 10 wt% of said gelling agent, for example about 7% to 10 wt% of of said gelling agent, for example about 7% to 9 wt% of of said gelling agent or such as 1, 2, 3, 4, 5, 6, 7, 8, or 9 wt% of said gelling agent.
  • the first and second composition of the kit is in dry form, such as a powder.
  • the invention provides the composition or kits of parts of the invention for use in the treatment of an infection in the mouth cavity, such as a dental infection.
  • composition or kits of parts is for use in the treatment of gingivitis, periodontitis, periimplantitis, endodontic infection. In one embodiment, the composition or kits of parts is for use in endodontic photoactivated disinfection.
  • a further aspect of the present invention provides a method of treating, ameliorating or reducing an infection in the mouth cavity, said method comprising the steps of (a) providing a composition of the present invention comprising at least one photosensitizer;
  • the infection subject to treatment or amelioration may for example be gingivitis, periodontitis, periimplantitis, endodontic infection.
  • the infection is in a periodontal pocket or a dental root canal.
  • the order to hold the disposed composition in the infected periodontal pocket or dental root for sufficient time composition may be applied in the form of an aqueous gel.
  • the composition is a gel and the gel is applied to one or more periodontal pockets.
  • the source of light may be any source of light emitting sufficient light in the blue spectrum to activate the photosensitizer(s).
  • the area of infection is illuminated with said light with an illumination intensity in the range of around 2000 to 7000 mW/cm 2 , such as in the range of 2000 to 6000 mW/cm 2 , for example in the range of 2000 to 5000 mW/cm 2 , such as in the range of 2000 to 4000 mW/cm 2 , for example 2000 to 3000 mW/cm 2 , such as 3000 mW/cm 2 .
  • the area of infection is illuminated with said light with an illumination intensity of around 2000 mW/cm 2 or around 12 J/cm 2 .
  • the area of infection is illuminated with said light for at least 30 seconds, such as 60 seconds, for example 1 minute, such as about 2 minutes, for example about 3 minutes, such as about 4 minutes, for examples about 5 minutes.
  • the area of infection is illuminated with said light with an illumination intensity of around 2000 mW/cm 2 or around 12 J/cm 2 and the area of infection is illuminated with said light for at least 30 seconds, such as 60 seconds, for example 1 minute, such as about 2 minutes, for example about 3 minutes, such as about 4 minutes, for examples about 5 minutes.
  • the light emitted from said source of light comprises light in the range of 380 to 520 nm, preferably 455 ⁇ 30 nm.
  • the source of light may be any source of light emitting sufficient light in the blue spectrum to activate the photosensitizer(s).
  • light is a blue light emitting diode (LED) or a blue light emitting optical fibre.
  • a dental curing light device that is also used for polymerization of light cure resin based composites typically emits light in the blue spectrum.
  • the infection in the mouth cavity typically comprises one or more one or more periodontal pathogenic microorganism.
  • the infection microorganism may be present as biofilm and or a planktonic infection.
  • the infection is primarily in the form of biofilm, such as a biofilm comprising one or more periodontal pathogenic microorganism.
  • pathogenic microorganism is selected from the group consisting of bacteria, fungi and virus.
  • the periodontal pathogenic microorganism is a bacterium.
  • the microorganism is a gram-negative bacterium.
  • the microorganism is a gram-positive bacterium.
  • the one or more microorganisms is selected from the group consisting of Porphyromonas gingivalis, Tannerella forsythia,
  • Fusobacterium nudeatum, Enterococcus faecal is, Streptococcus intermedius, Streptococcus mutans, Streptococcus gordonii, Prevotella intermedia and Actinomyces naeslundii.
  • the microorganisms is or comprises Porphyromonas gingivalis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition et un kit de pièces pour une thérapie photodynamique antimicrobienne et leurs utilisations, la composition comprenant (a) du peroxyde d'hydrogène, du peroxyde de carbamide et/ou de l'hypochlorite de sodium et (b) au moins un photosensibilisateur pouvant être activé par la lumière émise dans le spectre bleu, en particulier la curcumine, la riboflavine et l'érythrosine.
EP20808310.5A 2019-11-13 2020-11-11 Composition pour thérapie photodynamique antimicrobienne Withdrawn EP4058064A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201970694 2019-11-13
PCT/EP2020/081797 WO2021094396A1 (fr) 2019-11-13 2020-11-11 Composition pour thérapie photodynamique antimicrobienne

Publications (1)

Publication Number Publication Date
EP4058064A1 true EP4058064A1 (fr) 2022-09-21

Family

ID=73476087

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20808310.5A Withdrawn EP4058064A1 (fr) 2019-11-13 2020-11-11 Composition pour thérapie photodynamique antimicrobienne

Country Status (3)

Country Link
US (1) US20220409729A1 (fr)
EP (1) EP4058064A1 (fr)
WO (1) WO2021094396A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080734A1 (fr) * 2023-10-09 2025-04-17 Klang Gregg A Dispositifs de luminothérapie vaginale et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700575T1 (it) * 2009-07-17 2018-01-11 Klox Tech Inc Composizione orale antibatterica
MY150838A (en) * 2009-12-21 2014-02-28 Colgate Palmolive Co Oral care compositions for use with an oral light device
WO2011150004A2 (fr) * 2010-05-25 2011-12-01 The Procter & Gamble Company Compositions pour soins d'hygiène buccodentaire et procédés de fabrication de compositions pour soins d'hygiène buccodentaire contenant de la silice à partir de matériaux végétaux
US10745502B2 (en) * 2015-11-20 2020-08-18 Isp Investments Llc Polymers for oral care compositions
EP3463268B1 (fr) * 2016-05-23 2021-11-03 Klox Technologies Limited Compositions biophotoniques et utilisations de celles-ci

Also Published As

Publication number Publication date
US20220409729A1 (en) 2022-12-29
WO2021094396A1 (fr) 2021-05-20

Similar Documents

Publication Publication Date Title
Gursoy et al. Photodynamic therapy in dentistry: a literature review
de Oliveira et al. Photodynamic therapy in combating the causative microorganisms from endodontic infections
Pinheiro et al. Photodynamic therapy in endodontic treatment of deciduous teeth
EP0637976B1 (fr) Medicament pour la désinfection de la cavité buccale
CA2732307C (fr) Composition et methode de traitement des sdrm
Mahdi et al. Lethal effect of blue light-activated hydrogen peroxide, curcumin and erythrosine as potential oral photosensitizers on the viability of Porphyromonas gingivalis and Fusobacterium nucleatum
Afkhami et al. Evaluation of antimicrobial photodynamic therapy with toluidine blue against Enterococcus faecalis: Laser vs LED
Singh et al. Photodynamic therapy: An adjunct to conventional root canal disinfection strategies
Moradi et al. Antimicrobial action of photodynamic therapy on Enterococcus faecalis biofilm using curing light, curcumin and riboflavin
Beltes et al. Antimicrobial photodynamic therapy using Indocyanine green and near-infrared diode laser in reducing Entrerococcus faecalis
SIVIERI-ARAUJO et al. Photodynamic therapy in Endodontics: Use of a supporting strategy to deal with endodontic infection.
EP4058064A1 (fr) Composition pour thérapie photodynamique antimicrobienne
Khandge et al. Photodynamic therapy (part 1: applications in dentistry)
Bonstein et al. Photoactivated disinfection of Streptococcus intermedius through dentin disc at clinically relevant intervals: an in vitro study
Jurczyszyn et al. Potentiality of Photodynamic Therapy in Dentistry
Shuruthi et al. Role of photodynamic therapy in endodontics―a review
Srivastava et al. Enlightening the path of dentistry: Lasers–A brief review
Sachdeva Photodynamic therapy in dentistry: A literature review
Santana et al. Photosensitizers as potential culprits for compensatory benefits of aPDT in the treatment of peri‐implantitis: Unraveling the fundamental knowledge and bounded clinical applications of the aPDT
Hamblin Antimicrobial photodynamic therapy: new anti-infectives in the age of resistance
Voronkina et al. Efficiency of photodynamic inactivation Actinomyces israelii and Prevotella melaninogenica.
Hamidain et al. A Review of Blue Light Photodynamic Therapy in Management of Periodontitis
Krishnamachari Janani et al. Using photodynamic therapy in root canal system–A
WO2024200246A1 (fr) Kit de soins buccodentaires comprenant un dispositif électroluminescent et une composition orale
Araujo et al. Photodynamic therapy of cariogenic agents: A systematic review

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240423